title: Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles.
abstract: BACKGROUND
  Doxorubicin has a broad spectrum of anticancer activity, but its clinical application is limited due to serious side effects. The aim of this study was to explore a novel drug delivery system based on titanium dioxide (TiO(2)) nanoparticles for its potential role in enhancing the anticancer efficacy of doxorubicin while reducing its side effects.
  
  
  RESULTS
  Doxorubicin was loaded into TiO(2) nanoparticles by forming complexes with the transition metal, titanium, to construct doxorubicin-titanium dioxide (DOX-TiO(2)) nanocomposites as a drug delivery system. The anticancer activity of the DOX-TiO(2) nanocomposites was demonstrated by MTT assay, and the possible signaling pathway was explored by Western blot. In human SMMC-7721 hepatocarcinoma cells, our observations demonstrated that this drug delivery system markedly increased the efficiency of drug per dosage and decreased the IC(50), resulting in anticancer efficacy enhancement and side effect attenuation.
  
  
  CONCLUSIONS
  Such a doxorubicin delivery strategy is promising in cancer therapy. Apoptosis may contribute to the mechanism, due to protein expression of Bcl-2 being downregulated and that of Bax and caspase 3 being upregulated.
authors.affiliation: Key Laboratory of Medical Immunology and Department of Laboratory Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, People's Republic of China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
authors.forename: Ying
authors.initials: Y
authors.lastname: Wan
authors.forename: Yi
authors.initials: Y
authors.lastname: Wang
authors.forename: Haijun
authors.initials: H
authors.lastname: Zhang
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Jiao
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D015153:Blotting, Western; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D016503:Drug Delivery Systems; D006801:Humans; D020128:Inhibitory Concentration 50; D053768:Metal Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry / Q000648:ultrastructure; D046529:Microscopy, Electron, Transmission; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D014025:Titanium / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D001672:Biocompatible Materials; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; C009495:titanium dioxide; D004317:Doxorubicin; D014025:Titanium; D053148:Caspase 3
references.citation: Biomaterials. 2011 Mar;32(7):1906-14
references.pmid: 21145104
references.citation: Int J Nanomedicine. 2011;6:1415-27
references.pmid: 21796244
references.citation: J Control Release. 2000 Sep 3;68(3):419-31
references.pmid: 10974396
references.citation: Adv Drug Deliv Rev. 2008 May 22;60(8):886-98
references.pmid: 18374448
references.citation: Food Chem Toxicol. 2010 Jun;48(6):1425-38
references.pmid: 20385199
references.citation: Biomaterials. 2009 Sep;30(27):4708-15
references.pmid: 19500830
references.citation: Pharm Res. 2010 Sep;27(9):1848-60
references.pmid: 20596761
references.citation: Blood. 1996 Jul 15;88(2):386-401
references.pmid: 8695785
references.citation: Int J Nanomedicine. 2010 Dec 02;5:1079-84
references.pmid: 21170355
references.citation: Int J Nanomedicine. 2011;6:1027-34
references.pmid: 21720514
references.citation: Int J Nanomedicine. 2011;6:1487-96
references.pmid: 21796249
references.citation: J Nanosci Nanotechnol. 2011 Mar;11(3):1834-40
references.pmid: 21449318
references.citation: Eur J Pharmacol. 2011 Feb 10;652(1-3):82-8
references.pmid: 21114975
references.citation: Int J Nanomedicine. 2010 Aug 09;5:437-44
references.pmid: 20957165
references.citation: J Med Genet. 2009 Aug;46(8):497-510
references.pmid: 19505876
references.citation: Int J Nanomedicine. 2011;6:993-1003
references.pmid: 21720511
references.citation: Int J Nanomedicine. 2011;6:203-11
references.pmid: 21445276
references.citation: Biomaterials. 2006 Aug;27(23):4230-8
references.pmid: 16600364